ImmunityBio Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. D.Boral Maintained a Buy Rating on the Stock.
ImmunityBio Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. D.Boral Maintained a Buy Rating on the Stock.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.